Sandouk P, Chappey O, d'Yvoire M B, Scherrmann J M
INSERM U.26, Hôpital F. Widal, Paris, France.
Ther Drug Monit. 1995 Oct;17(5):544-8. doi: 10.1097/00007691-199510000-00018.
The myorelaxant thiocolchicoside (TC), an analogue of colchicine (COL), was assayed in plasma and urine by a radioimmunoassay (RIA) using a cross-reacting COL-specific polyclonal antibody. Cross-reactivity was 56% for TC, giving a limit of quantification of 0.5 ng/ml and a linear response from 0.5 to 100 ng/ml. Specificity was checked by cross-reactivity studies with COL analogues and by using liquid chromatography and RIA in tandem on urine samples. Two immunoreactive peaks were detected, but the nonspecific peak represented < 2% of the total urine concentration of TC. Pharmacokinetics of TC following infusion of 4 mg in two subjects revealed a moderate distribution (Vss from 31 to 35 L) and mainly extrarenal elimination (75% of the total body clearance). Terminal half-lives ranged from 2.4 to 2.7 h in plasma and from 3.2 to 3.7 h in urine.
使用与秋水仙碱(COL)交叉反应的特异性多克隆抗体,通过放射免疫分析法(RIA)对肌松剂硫代秋水仙碱(TC)进行血浆和尿液检测,TC是COL的类似物。TC的交叉反应率为56%,定量限为0.5 ng/ml,线性响应范围为0.5至100 ng/ml。通过与COL类似物的交叉反应研究以及对尿液样本串联使用液相色谱和RIA来检查特异性。检测到两个免疫反应峰,但非特异性峰占TC总尿液浓度的比例不到2%。两名受试者输注4 mg TC后的药代动力学显示分布适中(稳态分布容积为31至35 L),主要经肾外消除(占全身清除率的75%)。血浆中终末半衰期为2.4至2.7小时,尿液中为3.2至3.7小时。